Abstract
Introduction: Preoperative chemotherapy, based on cisplatin (CDDP), is essential to hepatoblastoma. Although the standard chemotherapy consists of CDDP and pirarubicin (hereafter, CITA) in Japan, we report here a case of intermediate-risk hepatoblastoma in a patient receiving CDDP monotherapy because of complication caused by initial CITA. Representative case: The representative case is that of a 1-year-old girl with PRETEXT III intermediate-risk hepatoblastoma. On the eighth day after open biopsy, we started CITA therapy. On the fourth day after initial CITA, she suffered from diffuse peritonitis caused by intestinal perforation. After the operation was performed, her myelosuppression and wound dehiscence were prolonged. We started CDDP monotherapy from Day 38 after the initiation of CITA. Subsequently, the therapy was completed on schedule with mild myelosuppression, and we were able to perform radical surgery. Conclusion: CDDP monotherapy may be one of the options for intermediate-risk hepatoblastoma with severe complications to avoid the prolongation of the interval of chemotherapy.
